Manhattan Scientifics (OTCMKTS:MHTX) & NOVONIX (NASDAQ:NVX) Head to Head Review

Manhattan Scientifics (OTCMKTS:MHTXGet Free Report) and NOVONIX (NASDAQ:NVXGet Free Report) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.


This table compares Manhattan Scientifics and NOVONIX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Manhattan Scientifics N/A N/A -320.17%

Institutional & Insider Ownership

0.1% of NOVONIX shares are owned by institutional investors. 11.8% of Manhattan Scientifics shares are owned by insiders. Comparatively, 23.7% of NOVONIX shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Manhattan Scientifics has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, NOVONIX has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.

Earnings & Valuation

This table compares Manhattan Scientifics and NOVONIX’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Manhattan Scientifics $50,000.00 N/A -$1.16 million N/A N/A
NOVONIX $8.05 million 29.59 -$46.25 million N/A N/A

Manhattan Scientifics has higher earnings, but lower revenue than NOVONIX.

Analyst Ratings

This is a summary of current recommendations for Manhattan Scientifics and NOVONIX, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Manhattan Scientifics 0 0 0 0 N/A
NOVONIX 0 0 1 0 3.00

NOVONIX has a consensus target price of $4.00, suggesting a potential upside of 105.13%. Given NOVONIX’s higher possible upside, analysts clearly believe NOVONIX is more favorable than Manhattan Scientifics.


NOVONIX beats Manhattan Scientifics on 7 of the 8 factors compared between the two stocks.

About Manhattan Scientifics

(Get Free Report)

Manhattan Scientifics, Inc., a technology incubator, engages in the development and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.


(Get Free Report)

NOVONIX Limited provides battery materials and development technology for battery manufacturers, materials companies, automotive original equipment manufacturers (OEMs), and consumer electronics manufacturers in North America, Asia, Australia, and Europe. It operates through Battery Materials and Battery Technology segments. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment, performs consulting services, and carries out research and development in battery development. The company is involved in the investment and real estate borrowing activities; and offers battery technology, battery testing hardware equipment, and battery testing and development consulting services. The company was formerly known as Graphitecorp Limited and changed its name to NOVONIX Limited in July 2017. NOVONIX Limited was incorporated in 2012 and is based in Brisbane, Australia.

Receive News & Ratings for Manhattan Scientifics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Manhattan Scientifics and related companies with's FREE daily email newsletter.